Astrazeneca

LUMOXITI

Manufacturer:

Astrazeneca

Lumoxiti HCPCS:

J9313

HCPCS Code Descriptor:

Injection, moxetumomab pasudotox-tdfk, 0.01 mg

Category:

J Code

Lumoxiti NDCs:

00310-4700-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00310-4700-01

About Lumoxiti:

LUMOXITI is an Oncology drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The J Code: J9313 is aligned to the drug LUMOXITI.

ACCESS PRICING AND MORE BY REGISTERING

J9313 Added Date:

October 1, 2019

J9313 Effective Date:

October 1, 2019

J9313 Termination Date:

HCPCS Active

Lumoxiti billing and coding information can be found through Astrazeneca at the link below:
Lumoxiti patient assistance information can be found through AstraZeneca Access 360 at the URL: https://www.myaccess360.com/home.html
LUMOXITI prescribing information can be found at the link below:
Information regarding LUMOXITI’s side effects can be found at MedlinePlus